Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Tirzepatide is a once-weekly injectable medication approved by the FDA for the treatment of type 2 diabetes (marketed as Mounjaro) and chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (marketed as Zepbound)
It is a membrane-permeable molecule, which means it can easily enter cells where NNMT operates
However, the overall absolute risk is still small, according to the researchers
Beyond glucose control, Tirzepatide also slows gastric emptying, meaning food takes longer to move from the stomach to the small intestine
The rationale above is mechanism-based community reasoning, not direct combination evidence
US$ 25.01
US$ 27.02
US$ 22.32
US$ 23.79
US$ 21.67
US$ 20.09
